The Pediatric Praziquantel Consortium

We are an international public-private partnership that aims to reduce the global disease burden of schistosomiasis by addressing the medical needs of infected children between the ages of 3 months and 6 years. By doing so, we hope to contribute to the ongoing efforts to eliminate schistosomiasis and improve child health.  

The impacts of schistosomiasis on child health development

What is schistosomiasis?

Schistosomiasis is a neglected tropical disease that affects an estimated 250 million people worldwide. It is one of the most important tropical diseases in terms of public health burden and economic impact. The existing ‘standard of care’ treatment for schistosomiasis is praziquantel, which is made available through mass drug administration programs to adults and school-aged children. It is, however, not suitable for children six years of age and younger. As such, around 50 million preschool-aged children currently lack adequate treatment. We are working to fill this treatment gap.

Share this page…